ESMO 2018 Conference Report

The European Society for Medical Oncology meeting has emerged as a premier stage for some of cancer’s biggest breakthroughs, including this weekend’s performance from AstraZeneca and Merck’s Lynparza in ovarian cancer maintenance; last year’s showing for AstraZeneca’s Imfinzi in stage 3 lung cancer; and 2016’s unveiling of results from key lung cancer studies for Merck & Co.’s Keytruda.

For all of the news from this year's conference, get the full report.

This exclusive report is for FiercePharma subscribers only.

Sign up or Confirm your subscription below